AI-driven discovery Biotech firm Proxima specializes in AI-driven drug discovery for proximity-based therapeutics, backed by a recent seed financing of 80M. This indicates strong investor confidence and a potential openness to partnerships around AI platforms, data tooling, and computational biology services.

Funding momentum Total funding reached 91M with significant seed support; combined with revenue in the mid tens of millions, this suggests growing operations and appetite for scalable collaborations in technology, data analytics, and platform integrations that accelerate R&D timelines.

AI & ML stack Proxima’s tech stack includes PyTorch, OpenAI, three.js, and other modern tooling, signaling potential collaboration opportunities in machine learning model development, AI hardware acceleration, generative AI workflows, and visualization/3D interfaces for drug design and molecular data.

Proximity therapeutics Specialization in proximity-based therapeutics points to needs in targeted delivery, biomarker analytics, high-throughput screening, and collaboration with contract research organizations and data providers that support spatial biology and precision medicine initiatives.

Growth & partnerships With 51-200 employees and a clear focus on biotech innovation, Proxima is positioned for strategic partnerships with analytics providers, cloud infrastructure, and specialized biotech SaaS platforms to scale research, data management, and early-stage clinical discovery.